Tunable Microfibers Suppress Fibrotic Encapsulation via Inhibition of TGFβ Signaling.
Fibrotic encapsulation limits the efficacy and lifetime of implantable biomedical devices. Microtopography has shown promise in the regulation of myofibroblast differentiation, a key driver of fibrotic encapsulation. However, existing studies have not systematically isolated the requisite geometric parameters for suppression of myofibroblast differentiation via microtopography, and there has not been in vivo validation of this technology to date. To address these issues, a novel lamination method was developed to afford more control over topography dimensions. Specifically, in this study we focus on fiber length and its effect on myofibroblast differentiation. Fibroblasts cultured on films with microfibers exceeding 16 μm in length lost the characteristic morphology associated with myofibroblast differentiation, while shorter microfibers of 6 μm length failed to produce this phenotype. This increase in length corresponded to a 50% decrease in fiber stiffness, which acts as a mechanical cue to influence myofibroblast differentiation. Longer microfiber films suppressed expression of myofibroblast-specific genes (αSMA, Col1α2, and Col3α1) and TGFβ signaling components (TGFβ1, TβR2, and Smad3). About 16 μm long microfiber films subcutaneously implanted in a mouse wound-healing model generated a substantially thinner fibrotic capsule and less deposition of collagen in the wound bed. Together, these results identify a critical feature length threshold for microscale topography-mediated repression of fibrotic encapsulation. This study also demonstrates a simple and powerful strategy to improve surface biocompatibility and reduce fibrotic encapsulation around implanted materials.
1 UCSF Department of Bioengineering and Therapeutic Sciences, San Francisco , California.
Jessica
J
Allen
2 UCSF Department of Dermatology, San Francisco , California.
Jubin
J
Ryu
3 California Institute of Technology , Department of Medical Engineering, Pasadena, California.
Alessandro
A
Maggi
1 UCSF Department of Bioengineering and Therapeutic Sciences, San Francisco , California.
Bianca
B
Flores
4 California Institute of Technology, Division of Engineering and Applied Science, Kavli Nanoscience Institute , Pasadena, California.
Julia R
JR
Greer
1 UCSF Department of Bioengineering and Therapeutic Sciences, San Francisco , California.
Tejal
T
Desai
D016475:3T3 Cells; D000818:Animals; D000943:Antigens, Differentiation / Q000096:biosynthesis*; D002454:Cell Differentiation; D005355:Fibrosis / Q000378:metabolism / Q000473:pathology; D008567:Membranes, Artificial; D051379:Mice; D058628:Myofibroblasts / Q000378:metabolism* / Q000473:pathology; D015398:Signal Transduction; D053773:Transforming Growth Factor beta1 / Q000378:metabolism*
D000943:Antigens, Differentiation; D008567:Membranes, Artificial; C508961:Tgfb1 protein, mouse; D053773:Transforming Growth Factor beta1